• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Participating Faculty: Hereditary Angioedema: Facilitating Diagnosis and Optimizing Clinical and Economic Outcomes

Publication
Article
Supplements and Featured PublicationsHereditary Angioedema: Facilitating Diagnosis and Optimizing Clinical and Economic Outcomes [CPE/CME
Volume 19
Issue 7 Suppl

This supplement to The American Journal of Managed Care reviews the pathophysiology, symptoms and clinical course, and diagnostic challenges of hereditary angioedema (HAE). The current therapeutic landscape for HAE is discussed with a focus on treatment for acute angioedema attacks, short- and long-term HAE prophylaxis, and home-based therapy. The supplement also describes the economic burdens of HAE, both direct and indirect, and how changes in treatment practices, such as the wider adoption of homebased therapy, may improve patient outcomes and reduce costs.Faculty

William J. Cardarelli, PharmD

Director of Pharmacy Revenue and Supply

Atrius Health

Harvard Vanguard Medical Associates

Watertown, Massachusetts

William R. Lumry, MD

Clinical Professor of Internal Medicine/Allergy

University of Texas Southwestern Medical School

Medical Director, AARA Research Center

Private Practice

Dallas, Texas

Contributing Editorial Support

Roderick A. Smith, MS

Medical-Science Communications Expert

Brighton, Massachusetts

This activity is supported by an educational grant from ViroPharma Incorporated.

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

William J. Cardarelli, PharmD, has no relevant financial relationships with commercial interests to disclose.

William R. Lumry, MD

Consultant: Biocryst, CSL Behring, Shire Human Genetic Therapies, ViroPharma Incorporated

Grants: CSL Behring, Dyax, Shire Human Genetic Therapies, ViroPharma Incorporated

Speakers’ Bureau: CSL Behring, Dyax, Shire Human Genetic Therapies, ViroPharma Incorporated

Roderick A. Smith, MS, has no relevant financial relationships with commercial interests to disclose.

The American Journal of Managed Care

Publishing Staff—Jeff D. Prescott, PharmD, RPh; Kara Guarini, MS; and Ida Delmendo have no relevant financial relationships with commercial interests to disclose.

PER and Pharmacy Times Office of Continuing Professional Education

Planning Staff—Judy V. Lum, MPA; and Elena Beyzarov, PharmD, and Ann C. Lichti, CCMEP, have no relevant financial relationships with commercial interests to disclose.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

© 2024 MJH Life Sciences
AJMC®
All rights reserved.